Tag: Cordis
BrosMed Medical announces Scott J Addonizio as chief operating officer
BrosMed Medical has announced the appointment of Scott J Addonizio as its chief operating officer (COO), effective immediately.
A press release details that Addonizio brings...
Cordis announces positive 24-month results from Selution SFA Japan trial
Cordis has announced positive 24-month results from the Selution SFA Japan trial. The prospective, multicentre, single-arm trial is designed to assess the safety and...
First RADIANCY results study shed light on safety and promising technical...
NOTE: This video is ONLY available to watch in selected countries and geographies
Vascular surgeon Raphael Coscas (Paris, France) and interventional cardiologist, Antoine Sauguet...
Cordis announces enrolment completion of the RADIANCY clinical study in Europe
Cordis has announced the completion of patient enrolment in the RADIANCY premarket clinical study. The prospective, multicentre, single-arm study is designed to evaluate the...
Vascular News’ top 10 most popular stories of October 2022
Five-year outcomes from the randomised SPACE-2 trial on carotid artery stenosis, an interview with Joseph S Coselli, and a report on the "significant" increase...
Cordis announces acquisition of MedAlliance
Cordis today announced its acquisition, subject to customary closing conditions including regulatory approvals, of MedAlliance.
A press release notes that the agreement includes an...
Cordis announces start of enrolment in RADIANCY clinical study in Europe
Cordis has announced the start of the RADIANCY premarket clinical study in Europe.
A press release details that RADIANCY is a prospective, multicentre, single-arm...
Vascular News’ top 10 most popular stories of June 2022
Coverage of this year's Leipzig Interventional Course (LINC; 6–9 June, Leipzig, Germany) and Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM; 15–18 June,...
Cordis announces successful first-in-human use of the Radianz radial peripheral system
Cordis recently announced the first-in-human use of the Radianz radial peripheral system by Jihad Mustapha at Advanced Cardiac & Vascular Centers (ACV) in Grand...
Vascular News’ top 10 most popular stories of March 2022
A review of intraoperative adverse events in patients treated with fenestrated and branched endovascular aneurysm repair, meta-analysis findings on peripheral arterial disease symptoms in...
Cordis makes strategic investment in E2, a developer of next-generation thrombectomy...
Cordis has announced a strategic investment venture that will expand the scope of the global cardiovascular technology company into the venous thromboembolism (VTE) market...
S.M.A.R.T. Radianz vascular stent system approved for transradial use in the...
Cordis recently announced that the US Food and Drug Administration (FDA) has approved the S.M.A.R.T. Radianz vascular stent system, a self-expanding stent purposefully engineered...
Jeremy Durack and John Simpson to join Cordis-X innovation accelerator
Ajax Health has announced the appointments of two cardiovascular professionals to Cordis-X, an independent accelerator created to drive innovation and growth to Cordis.
"Since the...
Vascular News’ top 10 most popular stories of December 2021
Highlights from the UK Vascular Societies’ Annual Scientific Meeting (VSASM 2021; 1–3 December, Manchester, UK), a VOYAGER PAD subanalysis, and Cordis' appointment of a...
Cordis names George Adams as chief medical officer
Cordis has announced George Adams as chief medical officer.
"We are delighted to have Dr Adams join our team as we continue to build the...
Cardinal Health completes sale of Cordis business to Hellman & Friedman
Cardinal Health and Hellman & Friedman (H&F) have revealed the completion of the previously announced sale of Cardinal Health's Cordis business to H&F. The...
Cardinal Health signs definitive agreement to sell its Cordis business to...
Cardinal Health recently announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately US$1...
OUTBACK™ Elite Re-entry catheter highly effective at saving limbs in extreme...
Lorenzo Patrone (London, UK) shares with BLearning at CIRSE 2019 (7–11 September, Barcelona, Spain) the benefits of using the OUTBACK™ Elite Re-entry Catheter (Cordis,...
INCRAFT AAA Stent Graft System receives FDA approval
Cordis has announced that the US Food and Drug Administration (FDA) has approved its INCRAFT AAA Stent Graft System for use in complex access...
FDA advisory committee votes in favour of INCRAFT for treatment of...
The US Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has provided a favourable recommendation on the...
